Poster | A Fully Integrated GPCR Antibody Discovery Workflow
Overcoming challenges in GPCRs with a fully integrated high-throughput antibody discovery workflow Download the poster Contact Us Poster Overview: Transform your approach to GPCR antibody discovery with this detailed poster that demonstrates how Alloy Therapeutics’ PerformAbTM yeast display platform and innovative technologies can overcome significant challenges in targeting these complex transmembrane proteins. Download the poster […]
Leveraging Human Lambda Light Chains in Antibody Discovery
Harnessing the potential of human lambda light chains in antibody discovery Download White Paper Contact Us Expanding antibody discovery potential with human lambda light chains Despite the kappa/lambda ratio in human circulation being between 1.5 and 2, therapeutic antibodies remain heavily biased toward kappa light chain usage. Our white paper explores how Alloy’s ATX-GL platform […]
Highly Specific anti-WT1/HLA-A2 TCRm Antibodies
New Data: unlocking the potential of TCRm antibodies Download the poster and explore the discovery of highly specific anti-WT1/HLA-A2 TCR-like antibodies. Download the poster Contact Us Keyway™ TCRm antibody discovery platform is revolutionizing immunotherapy development In a significant study, Alloy Therapeutics researchers identified T Cell Receptor mimic (TCRm) antibodies with exceptional specificity for the Wilms […]
Approaches to Binder Recovery Following Immunization Campaigns in Mouse Models
Harnessing the Potential of Human Lambda Light Chains in Antibody Discovery Campaigns
Fully Human Antibody Discovery Using Nanovials and Plasma Cells From ATX-GK™ Mice
Webinar Overview: Discover how to access previously untapped sources of high-affinity antibodies. In this presentation, Dr. Joe de Rutte from Partillion Bioscience and Dr. Dilip Challa from Alloy Therapeutics discuss how breakthrough technology can help: Access Plasma Cell Diversity: Discover how nanovial technology enables screening of plasma cells from ATX-GK transgenic mice harboring fully human […]
Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation
Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation. BOSTON, Mass. – September 20, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the formation of its scientific advisory board (SAB) that includes a group of renowned experts in fields spanning immunology, protein engineering, T cell receptor (TCR) modalities, and […]
Alloy Therapeutics to Empower Drug Discovery of Lundbeck’s Biologics for Brain Health
BOSTON, Mass. – May 2, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced it is collaborating with Lundbeck, a global pharmaceutical company specializing in brain diseases, in the discovery of novel biologics therapies. Through this agreement, Lundbeck will gain access to Alloy’s Antibody Discovery Services and its SeqImmune™ discovery module, which is a sequence-first workflow […]
Alloy Therapeutics Announces an Expansion of its Antibody Discovery Services in Conjunction with Two New Senior Vice Presidents
Alloy Antibody Discovery Services offers partners a modular campaign design that can meet their goals and budgets as they collaborate to discover the best antibodies with therapeutic potential. BOSTON, Mass. – April 26, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the appointment of Kent Bondensgaard and John “Lippy” Lippincott as the latest members […]
Alloy Therapeutics and Normunity Sign Multi-Program Antibody Discovery Collaboration in Immuno-Oncology
— Partnership leverages Alloy’s high velocity antibody discovery offering to accelerate Normunity’s novel precision immuno-oncology pipeline — BOSTON, MA; November 17, 2022—Alloy Therapeutics, a biotechnology ecosystem company, announced an antibody discovery collaboration spanning multiple precision immuno-oncology programs for Normunity, a biotech company that recently announced its $65 million Series A financing. The collaboration will support the […]